PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.66%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-7.81%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-18.38%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.60%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-18.76%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-17.86%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-17.86%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.91%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.81%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
6.82%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
4.17%
OCF growth under 50% of MRVL's 49.80%. Michael Burry might suspect questionable revenue recognition or rising costs.
6.33%
FCF growth under 50% of MRVL's 42.66%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
160.86%
10Y revenue/share CAGR under 50% of MRVL's 366.22%. Michael Burry would suspect a lasting competitive disadvantage.
43.38%
5Y revenue/share CAGR above 1.5x MRVL's 3.04%. David Dodd would look for consistent product or market expansions fueling outperformance.
-7.30%
Negative 3Y CAGR while MRVL stands at 9.19%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
168.15%
10Y OCF/share CAGR under 50% of MRVL's 994.08%. Michael Burry would worry about a persistent underperformance in cash creation.
26.50%
5Y OCF/share CAGR at 50-75% of MRVL's 40.52%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
5.20%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
137.70%
Below 50% of MRVL's 287.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
463.32%
Below 50% of MRVL's 4254.56%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-41.46%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
117.37%
10Y equity/share CAGR in line with MRVL's 108.60%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
36.69%
5Y equity/share CAGR at 75-90% of MRVL's 47.58%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
11.74%
3Y equity/share CAGR at 50-75% of MRVL's 20.45%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
2060.94%
Dividend/share CAGR of 2060.94% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
172.72%
Dividend/share CAGR of 172.72% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
129.94%
3Y dividend/share CAGR of 129.94% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-21.06%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
0.29%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.59%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-1.31%
We have a declining book value while MRVL shows 0.87%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.06%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.98%
Our R&D shrinks while MRVL invests at 3.82%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.86%
We cut SG&A while MRVL invests at 19.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.